Skip to content

The Effect of S-ketamine Combined With Sufentanil for Postoperative Analgesia in Patients Following Cesarean Section

The Effect of Low-dose of S-ketamine Combined With Sufentanil for Postoperative Patient-controlled Intravenous Analgesia in Patients Following Cesarean Section

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05299866
Enrollment
216
Registered
2022-03-29
Start date
2022-04-12
Completion date
2024-06-30
Last updated
2023-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Patient-Controlled, Cesarean Section, S-ketamine

Brief summary

This randomized controlled trial is designed to investigate the effect of low-dose of S-ketamine combined with sufentanil for postoperative patient-controlled intravenous analgesia in patients following cesarean section.

Interventions

DRUGS-ketamine

After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.

DRUGPlacebo

After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.

Sponsors

Ling Dong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists (ASA) physical status II * Patients aged between 20 and 40 years * 18 kg/m² ≤BMI≤30 kg/m² * singleton term pregnancy * scheduled for elective cesarean section

Exclusion criteria

* Refused to participant in this trial * Severe heart dysfunction or pulmonary insufficiency * Poor blood pressure control in those with hypertension (BP \>160/100 mmHg in the ward) * Previous history of Intracranial hypertension or hyperthyroidism * Previous history of schizophrenia, epilepsy, myasthenia gravis or delirium * Allergy to drugs used in the study

Design outcomes

Primary

MeasureTime frameDescription
The percentage of patients with moderate-to-severe painUp to 48 hours after surgeryModerate-to-severe pain is defined as a numeric rating scale (NRS; an 11-point scale where 0=no pain and 10=the worst pain) pain score ≥4.

Secondary

MeasureTime frameDescription
NRS pain score at rest and with movementHour 12 & Hour 24 & Hour 48 after surgeryPain is assessed with a numeric rating scale (NRS; an 11-point scale where 0=no pain and 10=the worst pain)

Other

MeasureTime frameDescription
The total number of presses of Patient-controlled Analgesia (PCA)Up to 48 hours after surgeryThe total number of presses of PCA
The percentage of using rescue analgesicsUp to 48 hours after surgeryThe percentage of using rescue analgesics
The Richmond Agitation-Sedation Scale(RASS)Hour 12 & Hour 24 & Hour 48 after surgerySedation is assessed with a numeric rating scale(RASS;an 10-point scale with -5 to +4)
The incidence of postoperative adverse eventUp to 48 hours after surgerypostoperative adverse event with nausea,vomiting,dizziness,nightmares, hallucination and etc

Countries

China

Contacts

Primary ContactLing Dong, Ph.D
dongling1668@163.com18866862815
Backup ContactLing Dong, MD
dongling1668@163.com18866862815

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026